ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptive Biotechnologies Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$23.95−0.07 (-0.29%)
Close on Oct 19, 2026
- Market cap
- $3.83B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
97.6%
156M of 160M shares
Institutional holders
300
49 new, 42 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 129 sales
Net sold $122.01M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Catherine D. Wood | 7,732,570 | 5.20% | 13G (passive) | Mar 31, 2025 |
| Viking Global Investors LP | 29,993,708 | 18.80% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 11,992,448 | 7.90% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ADPT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Viking Global Investors LP | 29,993,708 | 18.79% | $643.37M | – | 1.83% |
| BlackRock, Inc. | 15,139,159 | 9.49% | $324.73M | +1,836,134 | 0.00% |
| Vanguard Capital Management LLC | 6,403,587 | 4.01% | $137.36M | +309,443 | 0.00% |
| Wellington Management Group Llp | 5,911,366 | 3.70% | $126.80M | +2,053,944 | 0.02% |
| Vanguard Portfolio Management LLC | 5,476,231 | 3.43% | $117.47M | +984,757 | 0.01% |
| D. E. Shaw & Co., Inc. | 4,625,859 | 2.90% | $99.22M | +2,660,249 | 0.05% |
| Westfield Capital Management Co LP | 4,267,645 | 2.67% | $91.54M | −1,169,073 | 0.30% |
| Geode Capital Management, LLC | 3,641,837 | 2.28% | $78.13M | +5,783 | 0.00% |
| State Street Corp | 3,458,388 | 2.17% | $74.18M | +231,143 | 0.00% |
| Invesco Ltd. | 3,094,011 | 1.94% | $66.37M | −1,356,055 | 0.01% |
| Goldman Sachs Group Inc | 2,984,227 | 1.87% | $64.01M | −257,850 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 2,665,308 | 1.67% | $57.17K | +1,099,095 | 0.01% |
| Driehaus Capital Management LLC | 2,527,703 | 1.58% | $54.22M | +777,102 | 0.31% |
| Arrowstreet Capital, Limited Partnership | 2,524,620 | 1.58% | $54.15M | +529,418 | 0.02% |
| Lord, Abbett & Co. LLC | 2,474,814 | 1.55% | $53.09K | −1,061,289 | 0.15% |
| Nuveen, LLC | 2,366,155 | 1.48% | $50.75M | +1,061,995 | 0.01% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,182,326 | 1.37% | $46.81M | −505,755 | 0.05% |
| Fred Alger Management, LLC | 2,092,284 | 1.31% | $44.88M | +29,138 | 0.15% |
| ARK Investment Management LLC | 2,090,306 | 1.31% | $44.84M | −2,663 | 0.29% |
| Nomura Asset Management International Inc. | 1,889,188 | 1.18% | $40.52M | +8,005 | 0.06% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 300 | 156M | 97.6% | 49 / 109 | 89 / 42 | 24M | 20M |
| Q1 2026 | 298 | 152M | 95.2% | 57 / 101 | 96 / 38 | 34M | 21M |
| Q4 2025 | 283 | 150M | 94.2% | 52 / 100 | 92 / 38 | 29M | 24M |
| Q3 2025 | 271 | 146M | 91.3% | 55 / 93 | 81 / 25 | 20M | 23M |
| Q2 2025 | 242 | 149M | 93.1% | 46 / 92 | 63 / 26 | 22M | 29M |
| Q1 2025 | 225 | 155M | 97.1% | 40 / 73 | 67 / 19 | 29M | 17M |
| Q4 2024 | 207 | 143M | 89.8% | 46 / 67 | 45 / 23 | 13M | 13M |
| Q3 2024 | 187 | 144M | 90.2% | 32 / 65 | 45 / 20 | 23M | 17M |
| Q2 2024 | 177 | 150M | 93.8% | 25 / 70 | 45 / 37 | 25M | 19M |
| Q1 2024 | 190 | 144M | 90.3% | 28 / 57 | 68 / 37 | 14M | 14M |
| Q4 2023 | 200 | 145M | 90.8% | 38 / 59 | 72 / 26 | 13M | 9M |
| Q3 2023 | 190 | 141M | 88.5% | 16 / 59 | 75 / 34 | 15M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ADPT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,834,309 | 3.03% | $103.70M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,955,565 | 2.48% | $84.85M | 0.10% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 1,774,756 | 1.11% | $40.06M | 2.57% | Jul 31, 2026 |
| Vanguard Small-Cap Index Fund | 1,742,854 | 1.09% | $37.38M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,684,998 | 1.06% | $38.03M | 0.11% | Jul 31, 2026 |
| Alger Small Cap Focus Fund | 1,494,214 | 0.94% | $33.72M | 3.95% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,422,585 | 0.89% | $30.51M | 0.20% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,415,621 | 0.89% | $30.37M | 0.03% | Jun 30, 2026 |
| Oberweis Micro-Cap Fund | 1,215,600 | 0.76% | $26.07M | 1.61% | Jun 30, 2026 |
| Lord Abbett Developing Growth Fund Inc | 1,194,246 | 0.75% | $26.95M | 1.21% | Jul 31, 2026 |
| Invesco Main Street Small Cap Fund | 1,102,417 | 0.69% | $23.65M | 0.89% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,101,637 | 0.69% | $23.63M | 0.24% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,094,715 | 0.69% | $23.48M | 0.26% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 1,084,468 | 0.68% | $23.26M | 1.99% | Jun 30, 2026 |
| SmallCap Fund | 1,031,060 | 0.65% | $23.27M | 1.12% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Chad M. Robins | CEO and Chairman, Director | 3,030,722 | 1.90% | Aug 19, 2026 |
| Francis Lo | Chief People Officer | 315,331 | 0.20% | Sep 18, 2026 |
| Susan Bobulsky | Chief Commercial Officer, MRD | 395,794 | 0.25% | Sep 17, 2026 |
| Harlan S. Robins | Chief Scientific Officer | 2,104,458 | 1.32% | Jul 23, 2026 |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 299,532 | 0.19% | Jun 30, 2026 |
| Kyle Piskel | Chief Financial Officer | 256,725 | 0.16% | May 20, 2026 |
| Julie Rubinstein | President and COO | 396,839 | 0.25% | Apr 29, 2026 |
| Katey Einterz Owen | Director | 66,100 | 0.04% | Sep 2, 2026 |
| Robert Hershberg | Director | 77,347 | 0.05% | Aug 20, 2026 |
| Peter M. Neupert | Director | 255,315 | 0.16% | Aug 19, 2026 |
| Michelle Renee Griffin | Director | 15,625 | 0.01% | Jun 29, 2026 |
| Michael J. Pellini | Director | 69,690 | 0.04% | Mar 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Francis Lo Chief People Officer | Sep 16, 2026 | Option exercise | +15,629 | $3.99 | $62.36K | 312,831 |
| Francis Lo Chief People Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −7,869 | $28.57 | $224.82K | 220,867 |
| Francis Lo Chief People Officer | Sep 16, 2026 | Option exercise | +23,442 | $8.12 | $190.35K | 336,273 |
| Francis Lo Chief People Officer | Sep 16, 2026 | Option exercise | +13,398 | $8.46 | $113.35K | 297,202 |
| Francis Lo Chief People Officer | Sep 16, 2026 | Option exercise | +53,091 | $12.14 | $644.52K | 283,804 |
| Francis Lo Chief People Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −107,537 | $28.02 | $3.01M | 228,736 |
| Susan Bobulsky Chief Commercial Officer, MRD | Sep 15, 2026 | Sale(10b5-1 plan) | −1,195 | $27.00 | $32.27K | 395,794 |
| Katey Einterz Owen Director | Aug 31, 2026 | Gift | −12,539 | – | – | 66,100 |
| Katey Einterz Owen Director | Aug 26, 2026 | Sale | −9,615 | $26.00 | $249.99K | 78,639 |
| Robert Hershberg Director | Aug 18, 2026 | Option exercise | +15,000 | $6.32 | $94.80K | 77,347 |
| Robert Hershberg Director | Aug 18, 2026 | Sale | −15,664 | $24.41 | $382.36K | 46,683 |
| Robert Hershberg Director | Aug 18, 2026 | Sale | −15,000 | $24.39 | $365.85K | 62,347 |
| Chad M. Robins CEO and Chairman, Director | Aug 18, 2026 | Sale | −278,472 | $24.48 | $6.82M | 2,180,722 |
| Chad M. Robins CEO and Chairman, Director | Aug 18, 2026 | Sale | −204 | $25.14 | $5.13K | 2,180,518 |
| Chad M. Robins CEO and Chairman, Director | Aug 18, 2026 | Option exercise | +278,676 | $6.55 | $1.83M | 2,459,194 |
| Chad M. Robins CEO and Chairman, Director | Aug 17, 2026 | Sale | −318,799 | $25.08 | $8.00M | 2,183,043 |
| Chad M. Robins CEO and Chairman, Director | Aug 17, 2026 | Option exercise | +321,324 | $6.55 | $2.10M | 2,501,842 |
| Chad M. Robins CEO and Chairman, Director | Aug 17, 2026 | Sale | −2,525 | $25.57 | $64.56K | 2,180,518 |
| Peter M. Neupert Director | Aug 17, 2026 | Option exercise | +15,000 | $6.32 | $94.80K | 255,315 |
| Peter M. Neupert Director | Aug 17, 2026 | Sale | −15,000 | $25.23 | $378.45K | 240,315 |
| Peter M. Neupert Director | Aug 17, 2026 | Sale | −40,000 | $25.10 | $1.00M | 200,315 |
| Peter M. Neupert Director | Aug 17, 2026 | Sale | −69,690 | $25.16 | $1.75M | 130,625 |
| Susan Bobulsky Chief Commercial Officer, MRD | Aug 10, 2026 | Sale(10b5-1 plan) | −3,000 | $25.00 | $75.00K | 396,989 |
| Susan Bobulsky Chief Commercial Officer, MRD | Jul 30, 2026 | Sale(10b5-1 plan) | −1,299 | $24.00 | $31.18K | 399,989 |
| Harlan S. Robins Chief Scientific Officer | Jul 21, 2026 | Option exercise | +284,800 | $6.55 | $1.87M | 1,304,458 |
| Harlan S. Robins Chief Scientific Officer | Jul 21, 2026 | Sale(10b5-1 plan) | −278,698 | $21.72 | $6.05M | 1,025,760 |
| Harlan S. Robins Chief Scientific Officer | Jul 21, 2026 | Sale(10b5-1 plan) | −213,702 | $22.12 | $4.73M | 812,058 |
| Susan Bobulsky Chief Commercial Officer, MRD | Jul 16, 2026 | Sale(10b5-1 plan) | −5,000 | $23.00 | $115.00K | 401,288 |
| Francis Lo Chief People Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −105,762 | $22.59 | $2.39M | 230,713 |
| Francis Lo Chief People Officer | Jul 15, 2026 | Option exercise | +22,711 | $8.46 | $192.14K | 336,475 |
| Francis Lo Chief People Officer | Jul 15, 2026 | Option exercise | +59,374 | $7.80 | $463.12K | 290,087 |
| Francis Lo Chief People Officer | Jul 15, 2026 | Option exercise | +23,677 | $12.14 | $287.44K | 313,764 |
| Harlan S. Robins Chief Scientific Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −146,889 | $22.45 | $3.30M | 1,019,658 |
| Harlan S. Robins Chief Scientific Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −239,351 | $21.74 | $5.20M | 1,166,547 |
| Francis Lo Chief People Officer | Jul 2, 2026 | Option exercise | +12,626 | $7.80 | $98.48K | 250,314 |
| Francis Lo Chief People Officer | Jul 2, 2026 | Option exercise | +12,600 | $12.14 | $152.96K | 262,914 |
| Francis Lo Chief People Officer | Jul 2, 2026 | Option exercise | +12,637 | $8.46 | $106.91K | 275,551 |
| Francis Lo Chief People Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −44,838 | $22.59 | $1.01M | 230,713 |
| Susan Bobulsky Chief Commercial Officer, MRD | Jul 1, 2026 | Sale(10b5-1 plan) | −487 | $22.00 | $10.71K | 406,288 |
| Francis Lo Chief People Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −42,261 | $22.50 | $950.87K | 237,688 |
| Francis Lo Chief People Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −8,743 | $22.18 | $193.92K | 279,949 |
| Francis Lo Chief People Officer | Jul 1, 2026 | Option exercise | +14,064 | $8.12 | $114.20K | 288,692 |
| Francis Lo Chief People Officer | Jul 1, 2026 | Option exercise | +4,688 | $3.99 | $18.71K | 274,628 |
| Francis Lo Chief People Officer | Jul 1, 2026 | Option exercise | +12,206 | $8.46 | $103.26K | 269,940 |
| Francis Lo Chief People Officer | Jul 1, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 254,434 |
| Francis Lo Chief People Officer | Jul 1, 2026 | Option exercise | +3,300 | $12.14 | $40.06K | 257,734 |
| Sharon Benzeno Chief Commercial Ofc Imm Med | Jun 29, 2026 | Option exercise | +24,944 | $8.46 | $211.03K | 299,532 |
| Sharon Benzeno Chief Commercial Ofc Imm Med | Jun 29, 2026 | Option exercise | +51,570 | $8.12 | $418.75K | 376,046 |
| Sharon Benzeno Chief Commercial Ofc Imm Med | Jun 29, 2026 | Option exercise | +24,944 | $3.99 | $99.53K | 324,476 |
| Sharon Benzeno Chief Commercial Ofc Imm Med | Jun 29, 2026 | Sale(10b5-1 plan) | −154,768 | $21.14 | $3.27M | 221,278 |
| Sharon Benzeno Chief Commercial Ofc Imm Med | Jun 29, 2026 | Option exercise | +1,837 | $12.14 | $22.30K | 274,588 |
| Sharon Benzeno Chief Commercial Ofc Imm Med | Jun 26, 2026 | Sale(10b5-1 plan) | −11,034 | $21.00 | $231.71K | 272,751 |
| Sharon Benzeno Chief Commercial Ofc Imm Med | Jun 26, 2026 | Option exercise | +11,034 | $12.14 | $133.95K | 283,785 |
| Michelle Renee Griffin Director | Jun 25, 2026 | Sale(10b5-1 plan) | −52,084 | $20.18 | $1.05M | 15,625 |
| Michelle Renee Griffin Director | Jun 25, 2026 | Option exercise | +52,084 | $7.80 | $406.26K | 67,709 |
| Susan Bobulsky Chief Commercial Officer, MRD | Jun 25, 2026 | Sale(10b5-1 plan) | −5,000 | $20.50 | $102.50K | 406,775 |
| Harlan S. Robins Chief Scientific Officer | Jun 16, 2026 | Sale(10b5-1 plan) | −6,160 | $18.01 | $110.94K | 1,405,898 |
| Harlan S. Robins Chief Scientific Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −100,000 | $17.37 | $1.74M | 1,412,058 |
| Susan Bobulsky Chief Commercial Officer, MRD | Jun 11, 2026 | Sale(10b5-1 plan) | −5,000 | $19.00 | $95.00K | 411,775 |
| Susan Bobulsky Chief Commercial Officer, MRD | Jun 4, 2026 | Sale(10b5-1 plan) | −11,000 | $18.00 | $198.00K | 416,775 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Bobulsky Susan Officer | Oct 6, 2026 | 6,444 | $192.29K | Oct 6, 2026 | Restricted Stock Units |
| Rubinstein Julie Officer | Oct 1, 2026 | 379,777 | $10.98M | Oct 1, 2026 | Exercise of Stock Options |
| Lo Francis Officer | Sep 16, 2026 | 142,198 | $3.79M | Sep 16, 2026 | Exercise of Stock Options |
| Bobulsky Susan Officer | Sep 15, 2026 | 1,195 | $29.61K | Sep 15, 2026 | Restricted Stock Units |
| E. Owen Katherine Director | Aug 26, 2026 | 9,615 | $249.99K | Aug 26, 2026 | Restricted Stock |
| Robins Harlan Former Officer | Aug 20, 2026 | 402,160 | $10.23M | Aug 20, 2026 | Acquired as compensation -- Stock Options |
| Robins Harlan Former Officer | Aug 19, 2026 | 215,632 | $5.50M | Aug 19, 2026 | Acquired as compensation -- Stock Options |
| M. Hershberg Robert Director | Aug 18, 2026 | 30,664 | $748.30K | Aug 18, 2026 | Stock Option Exercise |
| Robins Chad Officer | Aug 18, 2026 | 278,676 | $6.84M | Aug 18, 2026 | Acquired as compensation -- Stock Options |
| Robins Harlan Former Officer | Aug 18, 2026 | 261,044 | $6.41M | Aug 18, 2026 | Acquired as compensation -- Stock Options |
| Neupert Peter Director | Aug 17, 2026 | 124,690 | $3.14M | Aug 17, 2026 | Stock Option Exercise |
| Robins Chad Officer | Aug 17, 2026 | 321,324 | $7.96M | Aug 17, 2026 | Acquired as compensation -- Stock Options |
| Robins Harlan Former Officer | Aug 17, 2026 | 300,992 | $7.46M | Aug 17, 2026 | Acquired as compensation -- Performance Awards |
| Bobulsky Susan Officer | Aug 10, 2026 | 3,000 | $74.79K | Aug 10, 2026 | Restricted Stock Units |
| Bobulsky Susan Officer | Jul 30, 2026 | 1,299 | $29.31K | Jul 30, 2026 | Restricted Stock Units |